Table 2.
Univariate analysis.
| No.patients | PFS | HR (95%CI) | p | OS | HR (95%CI) | p | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. events | Median PFS (months) (95%CI) | p | No.events | OS (months) (95%CI) | p | ||||||
| Overall | 95 | 74 | 11.00 (11.67–17.57) | — | — | — | 62 | 17.00 (17.72–23.04) | — | — | — |
| Age at diagnosis (years) | |||||||||||
| <56 | 48 | 37 | 10.45 (9.38–16.21) | 1.00 | 30 | 16.07 (14.98–21.89) | 1.00 | ||||
| ≥56 | 47 | 37 | 13.17 (11.57–21.40) | 0.217 | 0.834 (0.527–1.320) | 0.438 | 32 | 19.47 (18.26–26.47) | 0.143 | 0.811 (0.490–1.341) | 0.415 |
| Gender | |||||||||||
| male | 58 | 45 | 9.92 (9.91–17.00) | 1.00 | 37 | 15.67 (15.67–21.75) | 1.00 | ||||
| female | 37 | 29 | 11.87 (11.12–21.76) | 0.330 | 0.836 (0.522–1.338) | 0.456 | 25 | 18.70 (18.03–27.97) | 0.119 | 0.806 (0.484–1.341) | 0.406 |
| ECOG performance status | |||||||||||
| 0 | 55 | 40 | 15.27 (15.25–24.33) | 1.00 | 33 | 25.37 (22.06–29.66) | 1.00 | ||||
| 1 | 40 | 34 | 6.40 (5.89–9.13) | <0.001 | 3.53 (2.125–5.864) | <0.001 | 29 | 11.55 (10.91–14.77) | <0.001 | 5.194 (2.934–9.194) | <0.001 |
| Liver metastasis | |||||||||||
| Yes | 71 | 57 | 10.67 (10.90–16.22) | 1.00 | 44 | 17.73 (20.01–22.70) | 1.00 | ||||
| No | 24 | 17 | 11.17 (8.70–26.81) | 0.222 | 0.873 (0.506–1.506) | 0.626 | 18 | 13.33 (14.16–28.80) | 0.635 | 1.192 (0.687–2.071) | 0.532 |
| Lung metastasis | |||||||||||
| Yes | 43 | 34 | 10.00 (9.85–19.68) | 1.00 | 29 | 16.70 (16.38–23.92) | 1.00 | ||||
| No | 52 | 40 | 11.32 (10.80–18.20) | 0.931 | 0.929 (0.587–1.470) | 0.753 | 33 | 17.78 (16.72–24.41) | 0.878 | 0.867 (0.524–1.434) | 0.578 |
| M stage | |||||||||||
| M1a | 39 | 31 | 11.00 (10.79–21.13) | 1.00 | 26 | 19.47 (17.61–27.61) | 1.00 | ||||
| M1b | 56 | 43 | 10.65 (10.09–17.29) | 0.455 | 1.114 (0.700–1.774) | 0.648 | 36 | 16.50 (15.88–21.77) | 0.166 | 1.299 (0.738–2.046) | 0.428 |
| Chemotherapy regimen | |||||||||||
| FOLFOX | 26 | 14 | 10.99 (9.66–24.64) | 1.00 | 12 | 12.65 (13.21–24.71) | 1.00 | ||||
| FOLFIRI | 69 | 60 | 11.00 (10.63–16.71) | 0.298 | 1.553 (0.926–2.603) | 0.084 | 50 | 18.23 (17.87–23.95) | 0.518 | 1.361 (0.723–2.560) | 0.34 |
| Neutrophil counts | |||||||||||
| <3.6 | 46 | 30 | 14.60 (13.66–23.42) | 1.00 | 26 | 22.97 (18.99–27.17) | 1.00 | ||||
| ≥3.6 | 49 | 44 | 8.17 (7.67–14.21) | 0.010 | 2.406 (1.497–3.866) | <0.001 | 36 | 13.50 (14.41–21.27) | 0.050 | 2.095 (1.255–3.297) | 0.005 |
| Lymphocyte counts | |||||||||||
| <1.40 | 47 | 39 | 6.97 (7.70–16.04) | 1.00 | 33 | 13.40 (14.24–20.57) | 1.00 | ||||
| ≥1.40 | 48 | 35 | 14.07(13.14–21.50) | 0.066 | 0.542 (0.341–0.860) | 0.009 | 29 | 20.00 (19.09–27.49) | 0.027 | 0.585 (0.353–0.969) | 0.037 |
| Monocyte counts | |||||||||||
| <0.37 | 47 | 34 | 14.43 (12.76–22.00) | 1.00 | 31 | 22.67 (18.50–26.36) | 1.00 | ||||
| ≥0.37 | 48 | 40 | 7.92(8.22–15.61) | 0.066 | 1.753 (1.103–2.785) | 0.018 | 31 | 14.32 (14.73–22.01) | 0.130 | 1.398 (0.843–2.316) | 0.194 |
| Platelet counts | |||||||||||
| <195 | 47 | 35 | 9.90 (9.74–17.44) | 1.00 | 31 | 16.50 (15.67–23.45) | 1.00 | ||||
| ≥195 | 48 | 39 | 11.15 (11.04–20.21) | 0.496 | 0.995 (0.630–1.572) | 0.982 | 31 | 18.47 (17.41–24.94) | 0.550 | 0.855 (0.519–1.408) | 0.538 |
| NLR | |||||||||||
| <2.34 | 47 | 34 | 15.90 (15.22–24.17) | 1.00 | 29 | 24.37 (20.41–28.12) | 1.00 | ||||
| ≥2.34 | 48 | 40 | 6.84 (6.20–13.11) | 0.001 | 2.853 (1.774–4.588) | <0.001 | 33 | 12.90 (13.10–20.03) | 0.004 | 2.136 (1.286–3.548) | 0.003 |
| PLR | |||||||||||
| <142 | 48 | 34 | 13.99 (12.44–21.00) | 1.00 | 28 | 18.65 (17.78–26.39) | 1.00 | ||||
| ≥142 | 47 | 40 | (8.30–16.61) | 0.155 | 1.769 (1.113–2.810) | 0.016 | 34 | 13.50 (15.45–21.82) | 0.200 | 1.507 (0.908–2.502) | 0.113 |
| LMR | |||||||||||
| <4 | 48 | 37 | 6.97 (7.95–15.72) | 1.00 | 31 | 12.92 (13.84–21.28) | 1.00 | ||||
| ≥4 | 47 | 37 | 14.13 (13.02–21.91) | 0.058 | 0.644 (0.406–1.020) | 0.061 | 31 | 23.10 (19.49–27.01) | 0.033 | 0.664 (0.402–1.095) | 0.109 |
| SII | |||||||||||
| <460.66 | 48 | 36 | 13.99 (12.42–19.54) | 1.00 | 29 | 18.40 (17.64–25.10) | 1.00 | ||||
| ≥460.66 | 47 | 38 | 7.67 (8.39–18.06) | 0.356 | 1.554 (0.980–2.465) | 0.061 | 33 | 13.50 (15.45–23.27) | 0.456 | 1.386 (0.841–2.287) | 0.201 |
| LDHa | |||||||||||
| <220 | 58 | 41 | 11.60 (11.82–20.34) | 1.00 | 33 | 16.92 (16.85–24.27) | 1.00 | ||||
| ≥220 | 36 | 33 | 9.40 (8.41–16.03) | 0.213 | 1.636 (1.032–2.594) | 0.036 | 28 | 18.60 (16.41–24.19) | 0.926 | 1.424 (0.858–2.363) | 0.171 |
| CA19-9b | |||||||||||
| <22 | 48 | 39 | 12.25 (11.73–20.07) | 1.00 | 35 | 19.62 (17.96–24.63) | 1.00 | ||||
| ≥22 | 42 | 32 | 8.62 (8.34–16.35) | 0.222 | 1.249 (0.780–1.998) | 0.354 | 24 | 15.30 (14.45–22.70) | 0.300 | 1.016 (0.603–1.711) | 0.953 |
| CA-125c | |||||||||||
| <35 | 40 | 30 | 12.62 (10.59–17.66) | 1.00 | 25 | 17.38 (16.52–24.07) | 1.00 | ||||
| ≥35 | 12 | 10 | 7.55 (1.30–34.67) | 0.628 | 1.412 (0.686–2.907) | 0.349 | 7 | 15.68 (11.08–33.13) | 0.679 | 0.868 (0.375–2.013) | 0.742 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; CT, chemotherapy; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; SII, systemic immune-inflammation index; LDH, lactate dehydrogenase, CA19-9, carbohydrate antigen 19-9; CA-125, carbohydrate antigen-125; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
a94 were available; b90 were available; c52 were available.
A p value < 0.05 was considered statistically significant.